Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2024-11-20 00:00:00 ET · period of report 2024-11-19 · accession 0001415889-24-027348 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-20 | 2024-11-19 | ACRS | Mehra Anand | Dir | P - Purchase | $2.25 | +666.7K | 710.0K | +1,537% | +$1.50M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-19 | P | A | 666,666 | $2.25 | 710,030 | D | — | — | (F1) Represents shares of Common Stock of the Issuer acquired from the Issuer pursuant to Rule 16b-3(d). |